DelveInsight’s “Severe Psoriasis – Market Insight, Epidemiology And Market Forecast – 2032” report provides comprehensive coverage of the severe psoriasis treatment market, delivering in-depth analysis of historical and forecasted epidemiology alongside market drivers and challenges nacross the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report examines current treatment protocols, emerging therapies, market drivers, and barriers while offering detailed severe psoriasis market size forecasts from 2019 through 2032, positioning stakeholders to better understand the evolving treatment paradigm and commercial opportunities in this dynamic therapeutic area.
The severe psoriasis treatment market is rapidly evolving, driven by advancements in biologics, targeted therapies, and innovations in diagnostics and drug delivery. The United States currently captures the largest severe psoriasis market size due to the high prevalence of the disease, advanced healthcare infrastructure, and a strong inclination to adopt new therapies. Plaque psoriasis is the largest segment, representing over half of the overall market, thanks to its high prevalence and the introduction of new combination therapies. Meanwhile, psoriatic arthritis is anticipated to be the fastest-growing segment, reflecting increased awareness and improved diagnostic capabilities.
Download the Severe Psoriasis Market Forecast Report to understand which factors are driving the Severe Psoriasis therapeutic market @ Severe Psoriasis Market Trends.
Severe psoriasis epidemiological data reveal significant regional variations in the prevalence of moderate-to-severe psoriasis, affecting approximately 0.3% to 1% of the global population. In the US, the burden is notably higher, with nearly 8 million diagnosed psoriasis cases reported in 2023. About 20% to 30% of these cases are classified as moderate or severe. According to the analysis by DelveInsight, the patient population continues to grow across major markets, with demographic patterns showing variable gender distribution in different regions. The peak psoriasis incidence typically occurs between the ages of 20 and 60. Additionally, it has been observed that roughly one-third of cases begin in childhood.
Discover evolving trends in the Severe Psoriasis patient pool forecasts @ Severe Psoriasis Epidemiology Analysis.
The current severe psoriasis treatment landscape is dominated by biologic therapies targeting specific inflammatory pathways. BIMZELX from UCB, an interleukin-17A and interleukin-17F antagonist approved by the FDA in October 2023, has demonstrated superior efficacy in moderate-to-severe plaque psoriasis patients. The psoriasis therapeutic landscape also includes SOTYKTU, the first oral tyrosine kinase 2 (TYK2) inhibitor manufactured by Bristol Myers Squibb, alongside established interleukin-23 antagonists such as SKYRIZI (AbbVie), ILUMYA (Sun Pharma), and TREMFYA (Janssen Biotech). These targeted therapies represent a significant advancement over conventional systemic treatments and are rapidly gaining market share in treatment-refractory patient populations.
Several promising pipeline drugs are advancing the psoriasis treatment landscape, targeting different subtypes of the disease. Notable candidates include Picankibart (IBI112), a monoclonal antibody injection targeting IL-23, manufactured by Innovent Biologics; Icotrokinra (JNJ-2113), a first-in-class oral IL-23 inhibitor, manufactured by Johnson & Johnson; and Ebdarokimab (AK 101), an IL-12/23 monoclonal antibody, manufactured by Akeso, Inc.
For generalized pustular psoriasis, Imsidolimab (ANB019), an IL-36 receptor blocker, provided rapid and lasting relief, with over half of the patients achieving clear or almost clear skin in phase III studies. Other oral agents in development include piclidenoson (CF101), an A3 adenosine receptor agonist, and TYK2 inhibitors such as ESK-001 and ICP-488, both demonstrating significant symptom improvement in early trials.
Additionally, vibozilimod (SCD-044), an S1P1 receptor-1 agonist, is in phase II trials and shows potential for effective inflammation control. These pipeline drugs represent a new generation of targeted therapies aiming for higher efficacy, improved safety, and greater patient convenience.
Recent advancements in topical formulations are addressing the unmet needs in the severe psoriasis drug market. In March 2025, BIMZELX received further FDA approvals for psoriatic arthritis. Simultaneously, Johnson & Johnson announced Phase III results for icotrokinra, a first-in-class oral peptide that selectively blocks the IL-23 receptor. Nearly half of the patients achieved completely clear skin at 24 weeks, and the drug showed superiority to the oral TYK2 inhibitor deucravacitinib. This marks a potential shift toward oral therapies rivaling injectables in efficacy.
Discover evolving trends in the Severe Psoriasis treatment landscape @ Severe Psoriasis Recent Developments.
The major pharmaceutical companies dominating the severe psoriasis therapeutic market include Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), LEO Pharma, Novartis AG (SWX: NOVN), Biocon Biologics (NSE: BIOCON), AbbVie Inc. (NYSE: ABBV), Eli Lilly and Company (NYSE: LLY), Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA), Merck & Co., Inc. (NYSE: MRK), Evelo Biosciences, Inc. (NASDAQ: EVLO), Bausch Health Companies Inc. (NYSE: BHC), Amgen Inc. (NASDAQ: AMGN), Bristol-Myers Squibb Company (NYSE: BMY), Galderma S.A. (SIX: GALD), and InnoCare Pharma (HKEX: 9969), among others, investing heavily in novel mechanism approaches to address treatment gaps and improve patient outcomes.
The competitive landscape underscores substantial commercial interest in this therapeutic area, with significant research directed toward developing more effective and convenient treatment options for patients with severe forms of the disease. Furthermore, the introduction of biosimilars is intensifying competition, offering more cost-effective alternatives to originator biologics.
Looking ahead, the severe psoriasis market is poised for continued expansion driven by the introduction of novel oral targeted therapies, next-generation biologics with enhanced efficacy profiles, and combination regimens addressing multiple inflammatory pathways simultaneously. As understanding of disease pathophysiology advances, precision medicine approaches are expected to emerge, allowing for more personalized treatment strategies based on individual patient characteristics and biomarker profiles.
Table of Contents
1. Key Insights
2. Executive Summary of Severe Psoriasis
3. Competitive Intelligence Analysis for Severe Psoriasis
4. Severe Psoriasis: Market Overview at a Glance
5. Severe Psoriasis: Disease Background and Overview
6. Severe Psoriasis Patient Journey
7. Severe Psoriasis Epidemiology and Patient Population
8. Severe Psoriasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Severe Psoriasis Unmet Needs
10. Key Endpoints of Severe Psoriasis Treatment
11. Severe Psoriasis Marketed Products
12. Severe Psoriasis Emerging Therapies
13. Severe Psoriasis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Severe Psoriasis
17. KOL Views
18. Severe Psoriasis Market Drivers
19. Severe Psoriasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
